Cohort Studyhigh evidence
Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis.
JAMA neurology·October 22, 2026·PMID 42911175
Why it mattersAnti-CD20 therapies are widely used for multiple sclerosis, but emerging safety signals suggest a potential link to inflammatory bowel disease. This study quantifies that risk in a large, real-world cohort, providing clinicians with actionable data for treatment selection and monitoring.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled